NAMSNewAmsterdam Pharma Company N.V.
$19.70-46% 1Y
$19.70
$19.7052 weeks$41.45
Latest close: a new 52-week lowOct 23, 2026what changed →
Is the price fair?
What NAMS's price assumes
NewAmsterdam Pharma Company N.V. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 587× revenue.
587
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 6.63
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 6.63
- EV / EBIToperating margin −3432%: the multiple describes the denominator
- not meaningful
- Market capitalisation119.5 million shares, counted Aug 3, 2026
- $2.35B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.